PROGRAMS - Schizophrenia
Pro-cognitive Synaptic Modulators for Schizophrenia
Schizophrenia is a debilitating psychiatric disease characterized by disorders of thought, emotional disturbances and cognitive deficits. The disease is caused by a complex interplay of multiple genetic and environmental factors. It is now becoming apparent that these factors converge to cause alterations in synaptic transmission, the process by which neurons in the brain communicate with one another. This central feature of the disease is the key to a new therapeutic approach focused on identifying compounds that modulate synaptic function.
Using our MANTRA™ system, we have discovered and validated a novel synaptic functional signature of pro-cognitive efficacy. We are using this signature to drive optimization of a new class of pro-cognitive, synaptic modulators for schizophrenia. By applying our proprietary integrated in vivo EEG and behavioral measures to guide candidate selection, we are maximizing potential for success in the clinic. The goal of the program is a first-in-class, pro-cognitive antipsychotic therapy with an associated EEG biomarker to guide clinical development. Our pro-cognitive, anti-psychotic program is funded in part by a grant from the NIMH and by the Stanley Medical Research Institute.